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Summary
N-Acetyl-L-cysteine (NAC) is an antioxidant precursor of intracellular glutathione (GSH),
usually given in humans as a mucolytic agent. In vitro, NAC and GSH have been shown to act
on T cells by increasing interleukin (IL) 2 production, synthesis and turnover of IL-2 receptors,
proliferation, cytotoxic properties, and resistance to apoptosis. We report here that NAC and
GSH decrease in a dose-dependent manner human IL-4 production by stimulated peripheral
blood T cells and by T helper (Th) 0- and Th2-like T cell clones. This effect was associated
with a decrease in IL-4 messenger RNA transcription. In contrast, NAC and GSH had no ef-
fect on interferon y and increased IL-2 production and T cell proliferation. A functional conse-
quence was the capacity ofNAC and GSH to selectively decrease in a dose-dependent manner
IL-4-induced immunoglobulin (Ig) E and IgG4 production by human peripheral blood mono-
nuclear cells. Interestingly, NAC and GSH also acted directly on purified tonsillar B cells by
decreasing the mature e messenger RNA, hence decreasing IgE production. In contrast, IgA
and IgM production were not affected. At the same time, B cell proliferation was increased in a
dose-dependent manner. Not all antioxidants tested but only SH-bearing molecules mimicked
these properties. Finally, when given orally to mice, NAC decreased both IgE and IgG1 anti-
body responses to ovalbumin. These results demonstrate that NAC, GSH, and other thiols may
control the production of both the Th2-derived cytokine IL-4 and IL-4-induced Ig in vitro
and in vivo.
Acetyl-L-cysteine (NAC) is a thiol antioxidant usu-
ally used as a mucolytic drug (1), an antidote in acute
poisoning (2), and proposed as an anti-HIV agent (3) . NAC
is also a precursor of intracellular glutathione (GSH) (4, 5).
GSH is found in millimolar concentrations in most eukary-
otic cells and plays important roles in several cellular func-
tions (free radical scavenging, conjugation of toxic sub-
stances, and amino acid transport) (6) . Several studies have
indicated that NAC and GSH act on T cells by increasing
resistance to oxidative stress-mediated apoptosis (7), cyto-
toxic properties (4, 8, 9), synthesis and turnover ofIL-2 re-
ceptors, IL-2 production, and proliferation (8, 10). NAC
and some other thiol antioxidants have been reported to
regulate the activation of some transcription factors in-
'Abbreviations used in this paper: DTT, dithiothreitol; GSH, glutathione;
GS-SG, oxidized GSH; mRNA, messenger RNA; NAC, N-acetyl-L-
cysteine; NFKB, nuclear factor KB; SMC, S-methyl cysteine; SOD, su-
peroxide dismutase; TCC, T cell clones.
volved in IL-2 production; NAC decreases nuclear factor
KB (NF-KB) (11) and increases activator protein 1 tran-
scription factors (12) .
T cell responses have been divided in two subclasses, Thl
and Th2, according to the profile oflymphokines produced,
IFN-y and IL-2 or IL-4, IL-5, and IL-13, respectively. A
Thl response may favor cell-mediated immunity, whereas
a Th2 response provides help for Immoral responses, in-
cluding IgE and IgG4 (in humans) or IgGl (in mouse) iso-
type switching. Some pathologies are associated with an
abnormal predominant Thl or Th2 response (13) . Thus,
numerous studies are currently aiming at modulating lym-
phokine production by T cells. In view of the effects of
NAC on T cells, we have evaluated whether NAC could
selectively regulate Thl- or Th2-derived cytokine produc-
tion. We report here that NAC and GSH decreased IL-4
production by stimulated T cells and also acted on B cells
to selectively decrease IgE and IgG4 production. Both
these in vitro effects on T and B cells were associated with
an action at the transcriptional level on IL-4 and IgE mes-
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tion ofNAC also resulted in a decrease of IgE and IgG1 re-
sponses to ovalbumin.
Materials and Methods
Compounds Tested.
￿
NAC, S-methyl cysteine (SMC), reduced
GSH and oxidized GSH (GS-SG), captopril, D-penicillamine,
L-methionine, L-camitine, ascorbic acid, superoxide dismutase
(SOD), andcatalase were all purchased from Sigma Chemical Co.
(St Louis, MO). Dithiothreitol (DTT) was purchased from Ald-
rich (Buchs, Switzerland) . All the compounds were soluble in
culture medium, and thepH was adjusted to 7.4 before use.
Isolation of Peripheral Blood T Cells, Characterization of T Cell
Clones, and Isolation of Tonsillar B Cells. PBMC were isolated from
heparinized venous blood from healthy subjects by Ficoll-Hypaque
(Pharmacia, Uppsala, Sweden), and T cells were purified by ro-
setting with SRBC. The purity of T cells, determined by flow
cytometry on a FACStar® Plus cell sorter (BectonDickinson, Er-
embodegem, Belgium) using FITC-labeled mouse anti-human
CD3 mAb (Becton Dickinson), was >95%. The generation and
characterization of the human CD4+ Th0 and Th2-like T cell
clones (TCC) have been previously described (14, 15). T cells
were cultured in complete medium consisting of RPMI 1640
(GIBCO BRL, Basel, Switzerland) supplemented with 10% heat-
inactivated human AB' serum (CTS, Annemasse, France), 2 mM
glutamine, 20 mM sodium pyruvate (Sigma Chemical Co.), 50
p,g/ml streptomycin, and 50 U/ml penicillin (GIBCO BRL).
Human B cells were isolated from Ficoll-separated tonsillar
mononuclear cells by a two-step negative selection procedure us-
ing sheep cell rosetting andmagnetic bead depletion (Dynal, Oslo,
Norway) to remove T cells. B cell purity was routinely >98% as
determined by FRCS' analysis using FITC-labeled mouse anti-
CD20 andanti-CD3 mAbs (Becton Dickinson).
Induction ofLymphokine Production by T Cells.
￿
Purified T cells
were cultured in 96-well cell culture plates (Nuns, Roskilde,
Denmark) (4 X 105/200 p,l per well) and stimulated with 10 ng/
ml PMAplus 1 p,M ionomycin (Calbiochem Corp., LaJolla, CA).
T cell clones (2 X 105/200 p,l per well) were stimulated with 10
p,g/ml Con A (Sigma Chemical Co.) or with immobilized anti-
CD3 mAb. The stimulations were set up in the absence or pres-
ence of different concentrations of thiols. After 16 and 72 h of
culture, cell-free supernatants were collected and stored in ali-
quots at -70°C.
Quantification ofLymphokine in T Cell Supernatants.
￿
IL-2, IL-4,
IL-5, and IFN-y were quantified by ELISA as follows: IL-2, us-
ing two mAbs as previously described (sensitivity >200 pg/m1)
(16); IFN-y, usinga commercial kit (Genzyme Corp., Cambridge,
MA; sensitivity >100 pg/ml); and IL-4 and IL-5, using mAbs
from PharMingen (San Diego, CA) (sensitivity >100 pg/ml) .
Lymphokines were quantified in the 16-h supernatants except for
IL-5 produced afterstimulation with PMAplus ionomycin, which
was measured in the 48-h supernatants. Results are expressed in
nanograms per milliliter.
Induction of IgE Production by Tonsillar B Cells and by PBMC.
Tonsillar B cells and PBMC (2 X 105/200 p,l per well) were cul-
tured in 96-well culture plates in Iscove's medium enriched as
described (15). Purified B cells were stimulated with 200 U/ml
IL-4 (Glaxo Institute, Geneva, Switzerland) and 0.1 p,g/ml anti-
CD40 mAb (Serotec Kidlington, Oxford, UK). PBMC were in-
cubated with IL-4 alone or with IL-4 plus anti-CD40mAb. Both
these cultures were set up in the absence or presence of different
concentrations of thiols. After 14 d, cell-freesupernatants were col-
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lected and stored in aliquots at -70°C until tested for IgE, IgG4,
IgM, and IgA by ELISA as described (17). In kinetic experiments,
NAC was added to stimulated B cells either at the beginning of
the culture or at day4 or 7.
Proliferation Assays.
￿
TonsillarB cells (2 X 105/200 p,1 per well),
T cells, and TCC (2 X 104/200 p,Iper well) were cultured in 96-
well cell culture plates and stimulated in triplicate for either 3 d
with IL-4 plus anti-CD40 mAb for B cells, or 48 h with PMA
plus ionomycin or Con A for purified T cells and TCC, respec-
tively, with or without different concentrations ofthe thiols tested.
Cells were then pulsed for 6 h with [3H]thymidine (Amersham
International, Little Chalfort, UK) before measurement of radio-
activity. Results are expressed in counts per minute.
Molecular Analysis of IL-4 and IgE Transcripts by Northern Blot.
Tonsillar B cells were incubated for 8 d alone or in the presence
ofIL-4, IL-4 plus anti-CD40 mAb, or IL-4 plus anti-CD40 mAb
plus 10 mM NAC. T cells were stimulated for 6 h with PMA
plus ionomycin with or without 10 mM NAC. Total RNA was
isolated by extraction with RNAzol (Biotecx Laboratories Inc.,
Houston, TX) according to the manufacturer's instructions, sub-
jected to denaturing agarose electrophoresis (1 .5 p,g total RNA
perlane), transferred to a nylon' membrane, and fixed by UV ir-
radiation. Hybridizations with cRNA probes complementary to
CE mRNA and IL-4 mRNA were performed as described on B
and T cells, respectively (18) .
Flow Cytometric Analysis.
￿
After overnight incubation of puri-
fied human tonsillar B cells (2 X 105/200 p.l per well) with 200
U/ml IL-4 alone or in the presence of 0.5-20 mM NAC, the sur-
face phenotyping was performed by flow cytometry with FITC-
labeled mouse anti-human CD19 and anti-CD21 mAbs (Becton
Dickinson and Immunotech, Marseille, France, respectively) as
described (17) . The mouse anti-human CD40 mAb (Serotec)
was detected using a FITC-labeled goat anti-mouse Ab (Bioart,
Meudon, France). Control mouse IgG subclass Ab were all pur-
chased from Becton Dickinson.
Modulation of Ovalbumin-induced IgE Production in Mice Treated
with NAC. Female 6-8-wk-old C57BL/6JIbm mice (Biological
Research Laboratories, Fullinsdorf, Switzerland) were injected in-
traperitoneally with 1 Kg ovalbumin (Sigma Chemical Co.; grade
IV) and 2 mg aluminium hydroxide (Serva, Heidelberg, Ger-
many) to favor specific IgE response (19) . Mice drank water con-
taining 0.5, 1, or 2 g/liter NAC adjusted to pH 7.5 and changed
every 2 d. At differenttimes after immunization, levels oftotal IgG
and ovalbumin-specific IgE, IgGl, IgG2b, and IgM Ab were mea-
sured in sera by ELISA. Specific IgG1, IgG2b, and IgM were
quantified using affinity-purified peroxidase-labeled Ab (The
Binding Site, Birmingham, UK; Biosys, Compiegne, France).
Specific IgE was evaluated using a rat anti-mouse IgE mAb (20)
revealed by a mouse peroxidase-labeled anti-rat IgG Ab Qackson
ImmunoResearch Laboratories, Inc., West Grove, PA). Sera were
diluted at 1:4 for specific IgE, 1:100 for specific IgGl, IgG2a,
IgG2b, and IgM, and 1:10,000 fortotal IgG quantification .
Statistical Analysis.
￿
Statistical analysis was performed usingStu-
dent's t test.
Results and Discussion
Since NAC and GSH have been shown to increase pro-
liferation and IL-2 production by T cells (7, 8, 10), we in-
vestigated whether they may modulate Thl/Th2 lympho-
kine production by human T cells. Stimulation ofperipheral
blood T cells by PMA plus ionomycin or of TCC by anti-
CD3 mAb or Con A was set up in the presence or absenceof 0.5-20 mM NAC (Fig. 1) . Results showed that 0.5-20
mM NAC decreased in a dose-dependent manner IL-4
production by purified T cells (Fig. 1 a) and by Th0- and
Th2-like TCC (Fig. 1, b and c, respectively) stimulated for
16 h. In each case, a significant decrease was detected with
1 mM (P <0.05) and was maximal with 20 mM NAC.
Similar observations were made with three otherTCC (two
Th0 and one Th2 like) and with purified T cells stimulated
with anti-CD3 plus anti-CD28 mAbs (data not shown) .
The decrease of IL-4 production was not due to a toxic ef-
fect of NAC as assessed by trypan blue and propidium io-
dide staining of T cells stimulated in the presence of 20
mM NAC (data not shown). Moreover, in agreement with
others (7, 8, 10), we found that 0.5-20 mM NAC increased
in a dose-dependent manner the proliferation ofstimulated
T cells and TCC (Fig. 1 d) . GSH has been shown to in-
crease IL-4 internalization and degradation (21). Neverthe-
less, the decrease of IL-4 production induced by NAC was
associated with a decrease of IL-4 mRNA transcription
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(Fig. 2) . These data, reinforced by the fact that IL-4 was
quantified in the 16-h supernatants, allow us to exclude the
possibility that the decrease ofIL-4 production could result
only from its consumption by proliferative T cells. NAC
and DTT have been shown to regulate the activation of
some transcription factors: They decrease NFKB and in-
crease activator protein 1 expression (11, 12) . One can spec-
ulate that thiols may affect the activation of transcription
factors belonging to the NFkB family and implicated in the
transcription of IL-4 (such as nuclear factor of activated T
cells) (22). Further experiments are required to test this hy-
pothesis. In parallel to the decrease ofIL-4 production, IL-2
production was significantly increased by NAC up to 5 mM
(Fig. 1, a and b), as reported by others (10), whereas IFN-y
production was not affected whatever the time (Fig. 1, a
and b) . NAC did not affect IL-5 production by T cells and
Th0 TCC (Fig. 1, a and b) but decreased IL-5 production
by the Th2-like TCC (Fig. 1 c). This decrease in IL-5 could
be a consequence of the NAC-induced IL-4 reduction, as
10
Figure 1.
￿
NAC decreases IL-4 productionand in-
creases the proliferation of stimulated Tcells. Purified
T cells (a) and Th0 TCC (TT7) (b) were stimulated,
respectively, with PMA plus ionomycin or Con A in
the presence or absence of0.5-20 mM NAC. (a) IL-2
(X10) (A), IL-4 (X0.03) (O), and IFN-y (O) were
quantified in the 16-h supernatants by ELISA, and
IL-5 (O) in the 48-h supernatants. (b) Lymphokines
were quantified in the 16-h cell-free supernatants'. (c)
A Th2-like TCC (POD)was stimulated with Con A
(top) or with anti-CD3 mAb (bottom) with or without
0.5-20 mM NAC. (d) Purified T cells (O) and a
Th2-like TCC (POD) (0) were incubated, respec-
tively, with PMA plus ionomycin or Con A in the
presence of 0.5-20 mM NAC for 48 h and then
pulsed for 6 h with [3H]thynudine. Results of five
experiments ± SEM are presented.previously reported (23) . These data indicate that NAC,
while increasing T cell proliferation, preferentially de-
creases IL-4, and under some circumstances IL-5, but has
no effect on IFN-y .
A key function of IL-4 is its ability to induce IgE and
IgG4 production by human B cells (24, 25) . IgE produc-
tion by B cells also requires a` physical interaction with T
cells (26) or basophils and mast cells (27), involving a num-
ber of surface molecules including CD40 (28) and CD21
(29) . Based on the observation that NAC was able to de-
crease IL-4 production by T cells, we tested ifNAC would
also inhibit IL-4-induced IgE and IgG4 production by
PBMC . NAC decreased both IgE and IgG4 production in
a dose-dependent manner (IC50 = 1 rnM) (P <0.05) (data
not shown) . Even the superinduction of IgE and IgG4
PBMC
Figure 2 .
￿
NAC decreases IL-4
rnRNA transcription in stimu-
lated T cells . T cells were incu-
bated for 6 h alone or withPMA
plus ionomycin in the presence
or absence of 10 mM NAC .
RNA was isolated and used for
Northern blot analysis using
complementary probe for IL-4
(top) . As a control, the Northern
blot nylon membrane was
stained with methylene blue to
reveal rRNA (bottom) .
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brought about by addition of anti-CD40 mAb was de-
creased in a dose-dependent manner by NAC (IC S = 1 and
2 mM, respectively) (Fig. 3 a) . A significant decrease of IgE
and IgG4 was observed with 0.5 mMNAC (P <0.05) and
was maximal with 20 mM . In contrast, IgA and IgM iso-
types were not affected (Fig. 3 b) . Interestingly, NAC added
to highly purified B cells stimulated with anti-CD40 mAb
plus IL-4 also decreased to a higher extent IgE (IC_,,, = 0.3
nM) and IgG4 (IC50 = 0.8 mM), but not IgA and IgM
(Fig . 3, c and d), while increasingB cell proliferation (Fig . 4
a) . As observed for T cells, NAC was not toxic for B cells
as assessed by trypan blue and propidium staining (data not
shown) . Addition of NAC to IL-4 plus anti-CD40 mAb-
stimulated B cells at days 0, 4, and 7 revealed that the stron-
gest inhibitory effect ofNAC on IgE synthesis was observed
when NAC was added at day 0 . However, addition ofNAC
at day 4 or 7 still led to a significant reduction in the syn-
thesis of IgE (IC50 = 1 and 6 mM, respectively) (Fig . 4 b) .
Thus, one can speculate that NAC may have therapeutic
applications even on an ongoing IgE response .
To investigate the potential mechanism ofaction ofNAC
on IgE synthesis, the expressions of IgE transcripts and some
key cell surface molecules, CD21 and CD40, were analyzed .
The mature EmRNA transcript was decreased by NAC in
B cells stimulated with IL-4 plus anti-CD40 mAb . Con-
versely, the sterile EmRNA transcript was increased (Fig . 5
a) . NAC appears to be the first type of inhibitor ofIgE that
can selectively decrease the mature E transcript. The other
B cells
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Figure 3 .
￿
NAC decreases IgE and
IgG4 production by human B cells.
PBMC (a and b) and purified human
tonsillar B cells (c and d) were incu-
bated with IL-4 plus anti-CD40
mAb in the presence or absence of
different concentrations of NAC .
IgE
￿
(X 10-1)
￿
(0),
￿
IgG4
￿
(O),
￿
IgA
(A), and IgM (+) production were
quantified in the 14-d supernatants.
Data from one out of three repre-
sentative experiments are presented .reported IgE inhibitors, including IFN-y, IFN-o (30), and
TGF-(3 (18), inhibited both the mature and sterile e tran-
scripts . These results indicate that NAC can act downstream
of the IL-4-induced sterile e transcript by decreasing the
generation of the mature e mRNA . Finally, the expression
of CD21 and CD40 was decreased in a dose-dependent
manner by treatment ofpurified B cells stimulated with IL-4
in the presence ofNAC (Fig. 5 b) . The expression ofCD21
was totally inhibited with 20 mM NAC, whereas the ex-
pression ofCD40 was only partly reduced (50% of decrease) .
The expression ofotherB cell markers, such as CD19 (Fig .
5 b), CD11a, and CD20 (not shown), was unaffected . In fact,
CD40-CD40 ligand interaction is essential for the switch-
ing process that takes place during the first 2 and 3 d ofthe
B cell assays (Lecoanet-Henchoz, S ., unpublished results) .
The partial decrease of CD40 expression induced byNAC
cannot account for the total inhibition of the mature e
mRNA expression . First, NAC still promotes B cell prolif-
eration, although CD40 expression is decreased. Second,
the ability ofNAC added at day 7 to decrease IgE produc-
tion cannot be explained only by a decrease of CD40 . The
NAC-induced disappearance ofCD21 expression could be
responsible since the CD23-CD21 interaction favors the
91
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Figure 4 .
￿
NAC increases tonsillar B cell proliferation while decreasing
IgE production in a time-dependent manner . (a) Tonsillar B cells were
stimulated with IL-4 plus anti-CD40 mAb with or without 0.1-20 mM
NAC for 3 d and then pulsed for 6 h with ( 3H]thymidine . (b) Tonsillar B
cells were stimulated with IL-4 plus anti-CD40mAb and 1-20 MM NAC
added either at the beginning (O), at day 4 (O), or day 7 (A) ofthe cul-
ture . IgE was quantified in the 14-d supernatants . a and b present data
from one (out ofthree) representative experiment.
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generation of IgE-producing B cells (31) . Taken together,
these effects of NAC on IL-4 production, mature e
mRNA transcription, and the expression of surface mole-
cules involved in IgE regulation could at least partly explain
the decrease ofhuman IgE production in vitro .
Figure 5 .
￿
NAC decreases mature e mRNA, CD21, and CD40 expres-
sion on human tonsillar B cells . (a) Purified tonsillar B cells were incu-
bated for 8 d alone or in the presence of IL-4, IL-4 plus anti-CD40 mAb,
or IL-4 plus anti-CD40 mAb plus 10 mM NAC . RNA was isolated and
used for Northern blot analysis using probes complementary to CE . The
lefthand upper panel shows an autoradiograph from a 12-h exposure
(alone ± IL-4) . The righthand upper panel shows a 1-h exposure (IL-4 +
otCD40 ± NAC) . As a control, the Northern blot nylon membrane was
stained with methylene blue (bottom) . (b) After overnight incubation o£
tonsillar B cells with IL-4 alone or in the presence ofdifferent concentra-
tions of NAC, the expression ofCD19 (O), CD21 (O), and CD40 (A)
was evaluated by cytometry. Results from one (out of three) representa-
tive experiment are expressed in percentage ofdecrease ofexpression .These in vitro findings were extended to an in vivo mouse
model. Mice were treated with ovalbumin to induce an IgE
response and were given NAC dissolved in drinking water.
1 wk after immunization, both ovalbuniin-specific IgE and
IgG1 (the mouse isotype equivalent to human IgG4) re-
sponses were highly reduced (68 and 78% inhibition at 1
g/liter ofNAC, respectively) compared with untreated an-
imals (Fig. 6) . A significant decrease was also observed us-
ing 0.5 g/liter of NAC but not with lower concentrations
(data not shown). 2 wk after immunization, the inhibitory
effect of NAC on IgE and IgG1 responses was still ob-
served (30 and 32% decrease, respectively). The synthesis of
the other Ig isotypps was not significantly affected, in
agreement with the in vitro findings. On the basis of the
volume of water drunk in 1 d, the quantity of NAC swal-
lowed by a mouse could be estimated at 50 mg/kg per day,
comparable with 9 and 300 mg/kg per day given in hu-
mans as a mucolytic or as an antidote in poisoning, respec-
tively. This suggests that NAC acts in a range of doses that
are already used in human therapeutics. These results sug-
gest that in vivo NAC selectively down-regulates the pro-
duction of antigen-specific IgE and IgG1 Ab, the two iso-
types regulated by mouse IL-4 (32) .
To investigate if antioxidants, in addition to NAC, simi-
larly reduce IL-4 and IgE production, we tested the com-
pounds listed in Table 1. The antioxidants without an SH
group (such as L-carnitine, catalase, ascorbic acid, and SOD)
and the molecules without a free thiol (such as methionine,
SMC, and GS-SG) had no activity. It appears that free SH
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groups are critical for molecules to decrease IL-4 and IgE
production. This was the case for NAC, GSH, DTT, and
also for captopril and D-penicillamine, two drugs used in
humans. In agreement with others, we found that GSH in-
creased IL-2 production by T cells (data not shown) and T
cell proliferation (Table 1) (7, 8, 10). Whereas GSH, capto-
pril. and D-penicillamine used from 0.5 to 20 mM were as
potent as NAC in decreasing IL-4 and IgE synthesis, the
dithiol DTT was the most efficient (ICs0 = 0.5 and 0.2
mM, respectively) .
NAC and GSH are able to increase IL-2 production and
use T cell proliferation, and to decrease T cell apoptosis
(7, 8, 10) . Because ofits ability to restore intra- and extra-
cellular GSH levels and to decrease HIV replication (33,
34), NAC has been proposed in the treatment of HIV in-
fection (3, 5). It has been suggested that, during AIDS, a
switch of the T cell cytokine pattern from a Thl to a
Th2 type could be associated with a poor prognosis (35) .
Moreover, IL-4-deficient mice have been shown to be re-
sistant to retrovirus-induced immunodeficiency syndrome
(36), and it has been very recently reported that NAC in-
duced a decrease ofIL--4 production by HIV-infected cells
(37). We report here that NAC decreases synthesis of the
Th2-derived cytokine IL-4 and IL-4-induced Ig produc-
tion while increasing B and T cell proliferation. Experi-
ments are in progress to define the molecular target(s) of
thiols, as they may constitute new therapeutic molecules
to treat Th2-mediated diseases such as allergic disorders
and AIDS.
Figure 6.
￿
Oral administration of NAC decreases
specific IgE and IgGl Ab responses in ovalbumin-
immunized mice. C57BL/6JIbm mice injected in-
traperitoneally with ovalbumin drank water con-
taining (+) or not (-) 1 g/liter NAC. 8 d after
immunization, IgE, IgGI, IgG2a, IgG2b, and IgM
Abs directed against ovalbumn and polyclonal IgG
were measuredResults are expressed in OD val- +
￿
.
ues. Results from oneset of experiments with nine
mice per group are presented.
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￿
Thiol-containing Compounds Selectively Decrease IL-4 and IgE/IgG4 Production
Nonantioxidant
SMC
Methionine
GS-SG
Summary of theeffects ofNAC andothercompounds on lymphokine production, proliferation, and IgE/IgG4 production by humanlymphocytes,
Three sets of compounds were tested: (a) antioxidants with a free thiol group (0.5-20 mM, NAC; 0.5-20 mM, reduced GSH; 0.1-2 mm, DTT;
0.5-20 mM, captopril; and0.5-20 mM, D-penicillamine); (b) antioxidants withoutafree thiol group (0.5-20mM, L-camitine; 50-400 U/ml, cata-
lase; 10-100 p,M, ascorbic acid; 10-400 U/ml, SOD); and (c) S-substitutedcompounds (SMC, 0.1-20mM; methionine, 0.1-20 mM; GS-SG, 0.1-
10 mM). Purified peripheral blood T cells were stimulated with PMAplus ionomycin in the presence or absence of the compounds tested. Prolif-
eration assays were then performed as described in Materials andMethods, and lymphokines were measured by ELISA in the 24- and 72-h cell-free
supernatants. PBLsynthesis of IL-4-dependent Ig was evaluated using the in vitro assay described in Materials and Methods in the presence or ab-
sence of the compoundstested.
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